{"id":"W4410799986","doi":"10.1016/s2352-3026(25)00051-1","title":"Beyond maximum grade: tolerability of immunotherapies, cellular therapies, and targeted agents in haematological malignancies","year":2025,"lang":"en","type":"review","venue":"The Lancet Haematology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"National Cancer Institute; Astellas Pharma; Swedish Orphan Biovitrum; Else Kröner-Fresenius-Stiftung; Incyte; BeiGene; Eli Lilly and Company; AstraZeneca; Arnold Ventures; Adaptive Biotechnologies; Gilead Sciences; Sanofi; Amgen; National Heart, Lung, and Blood Institute; Pfizer; Seagen; Cidara Therapeutics; National Institute of Allergy and Infectious Diseases; Celgene; GlaxoSmithKline","keywords":"Medicine; Tolerability; Oncology; Immunotherapy; Internal medicine; Intensive care medicine; Adverse effect; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001652021,0.0006782862,0.008143624,0.0004361626,0.00009992574,0.00002741143,0.0008438682,0.0008437851,0.001252309],"category_scores_gemma":[0.0003093605,0.0004109819,0.0005259038,0.0008818359,0.001249103,0.00004146971,0.0004016809,0.001358665,0.00001712189],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000143787,"about_ca_system_score_gemma":0.0005243448,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001404334,"about_ca_topic_score_gemma":0.00004958013,"domain_scores_codex":[0.9948128,0.001635379,0.001446828,0.0007842218,0.0004381172,0.0008826025],"domain_scores_gemma":[0.9961634,0.001470197,0.0004824889,0.001663407,0.0001208511,0.00009961771],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.001470225,0.001434514,0.008097814,0.2091984,0.00288026,0.002783794,0.002526915,7.552357e-7,0.0007742955,0.0173087,0.005869719,0.7476546],"study_design_scores_gemma":[0.003179243,0.0003401646,0.0007470294,0.01204686,0.0007815146,0.002383913,0.0001794011,0.00001036935,0.0002792876,0.01129195,0.9681517,0.0006085444],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.009536797,0.9844064,0.00001779751,0.001708119,0.0002551234,0.002759951,0.00009116399,0.00007375814,0.001150897],"genre_scores_gemma":[0.001763008,0.9957379,0.0002805173,0.0003667535,0.00009449491,0.000354565,0.0001387763,0.00006407547,0.001199881],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.962282,"threshold_uncertainty_score":0.9998342,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09745188310624656,"score_gpt":0.3748129590262169,"score_spread":0.2773610759199703,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}